EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Macrophage activation markers are associated with infection and mortality in patients with acute liver failure

Anna Cavazza, Evangelos Triantafyllou, Roberto Savoldelli, Salma Mujib, Ellen Jerome, Francesca M Trovato, Florent Artru, Roosey Sheth, Xiao Hong Huang, Yun Ma, Francesco Dazzi, Tasneem Pirani und 5 weitere

Liver International · 2024

DOI: 10.1111/liv.15928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Anna Cavazza und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inflammation Biology, School of Inflammation and Microbial Science, Institute of Liver Studies, King's College London, London, UK. Hauptthemen laut MEDLINE: Liver Failure, Acute, Biomarkers, Macrophage Activation, Receptors, Cell Surface. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Medical Research Council, UK, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Acute liver failure is a multisystem disorder with a high mortality and frequent need for emergency liver transplantation. Following massive innate immune system activation, soluble markers of macrophage activation are released during liver damage and their association with disease severity and prognosis requires exploration.

Methods

Patients ALF from the United States Acute Liver Failure Study Group (USALFSG, n = 224) and King's College Hospital ( n = 40) together with healthy controls (HC, n = 50) were recruited. Serum from early (Days 1–3) and late (>Day 3) time points were analysed for MAMs by enzyme‐linked immunosorbent assay correlated to markers of illness severity and 21‐day spontaneous survival. Surface expression phenotyping was performed via Flow Cytometry on CD14 + monocytes.

Results

All MAMs serum concentrations were significantly higher in ALF compared to controls ( p < .0001). sCD206 concentration was higher in early and late stages of the disease in patients with bacteraemia ( p = .002) and infection in general ( p = .006). In MELD‐adjusted multivariate modelling, sCD206 and sCD163 were independently associated with mortality. CD14 + monocyte expression of CD206 ( p < .001) was higher in patients with ALF compared with controls and correlated with SOFA score ( p = .018). sCD206 was independently validated as a predictor of infection in an external cohort. Conclusions sCD206 is increased in serum of ALF patients with infections and poor outcome and is upregulated on CD14 + monocytes. Later measurements of sCD163 and sCD206 during the evolution of ALF have potential as mechanistic predictors of mortality. sCD206 should be explored as a biomarker of sepsis and mortality in ALF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Failure, AcuteBiomarkersMacrophage ActivationReceptors, Cell SurfaceAntigens, Differentiation, MyelomonocyticHumansMaleFemaleMiddle AgedAdultCase-Control StudiesAntigens, CDSeverity of Illness IndexLipopolysaccharide ReceptorsPrognosisLectins, C-TypeMonocytesMannose ReceptorEnzyme-Linked Immunosorbent AssayMannose-Binding LectinsUnited StatesMultivariate AnalysisFlow CytometryAgedCD163 Antigen

Stichwörter der Autor:innen

acute liver failureinnate immunitymacrophagesorgan failuresepsis

Substanzen

BiomarkersCD163 AntigenReceptors, Cell SurfaceAntigens, Differentiation, MyelomonocyticAntigens, CDLipopolysaccharide ReceptorsLectins, C-TypeMannose ReceptorMannose-Binding Lectins

Autor:innen und Institutionen

  • Department of Inflammation Biology, School of Inflammation and Microbial Science, Institute of Liver Studies, King's College London, London, UK.
  • Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital, London, UK.
  • Section of Hepatology and Gastroenterology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • School of Cardiovascular and Metabolic Medicine and Science, King's College London, London, UK.
  • Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Division of Gastroenterology (Liver Unit), Department of Critical Care Medicine, University of Alberta, Edmonton, Canada.

ORCID-Profile: William M Lee, Mark J McPhail, Constantine J Karvellas

Förderung

  • Medical Research Council
  • Medical Research Council, UK
  • NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health

Zitieren

APA

Cavazza, A., Triantafyllou, E., Savoldelli, R., Mujib, S., Jerome, E., Trovato, F. M., Artru, F., Sheth, R., Huang, X. H., Ma, Y., Dazzi, F., Pirani, T., Antoniades, C. G., Lee, W. M., McPhail, M. J., Karvellas, C. J., & US Acute Liver Failure Study Group (2024). Macrophage activation markers are associated with infection and mortality in patients with acute liver failure. Liver International. https://doi.org/10.1111/liv.15928

Vancouver

Cavazza A, Triantafyllou E, Savoldelli R, Mujib S, Jerome E, Trovato FM, et al. Macrophage activation markers are associated with infection and mortality in patients with acute liver failure. Liver International. 2024. doi:10.1111/liv.15928

BibTeX
@article{Cavazza2024,
  author = {Cavazza, Anna and Triantafyllou, Evangelos and Savoldelli, Roberto and Mujib, Salma and Jerome, Ellen and Trovato, Francesca M and Artru, Florent and Sheth, Roosey and Huang, Xiao Hong and Ma, Yun and Dazzi, Francesco and Pirani, Tasneem and Antoniades, Charalambos G and Lee, William M and McPhail, Mark J and Karvellas, Constantine J and US Acute Liver Failure Study Group, US Acute Liver Failure Study Group},
  title = {Macrophage activation markers are associated with infection and mortality in patients with acute liver failure},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15928}
}
Kostenlos starten →